Document is current
Any future updates will be listed below
-
Authors
Nozu, Kandai http://orcid.org/0000-0002-0290-3137
Nakanishi, Koichi
Abe, Yoshifusa
Udagawa, Tomohiro
Okada, Shinichi
Okamoto, Takayuki
Kaito, Hiroshi
Kanemoto, Katsuyoshi
Kobayashi, Anna
Tanaka, Eriko
Tanaka, Kazuki
Hama, Taketsugu
Fujimaru, Rika
Miwa, Saori
Yamamura, Tomohiko
Yamamura, Natsusmi
Horinouchi, Tomoko
Minamikawa, Shogo
Nagata, Michio
Iijima, Kazumoto
-
Funding
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (H24-nanchitou (nan)-ippan-041)
Japan Agency for Medical Research and Development (7930006)
Ministry of Education, Culture, Sports, Science and Technology (15K09691, 17H04189)
- License Information
-
More Information
Article History
Received: 12 April 2018
Accepted: 6 August 2018
First Online: 20 August 2018
Compliance with ethical standards
:
: Kazumoto Iijima has received grant support from Daiichi Sankyo Co. Ltd. He has also received consulting fees from Takeda Pharmaceutical Company and Kyowa Hakko Kirin Co. Ltd. Kandai Nozu has received lecture fees from Novartis Pharmaceuticals Corporation. Kazumoto Iijima and Kandai Nozu have filed a patent application on the development of antisense nucleotides for exon skipping therapy in Alport syndrome. The remaining authors have declared that no conflict of interest exists.
: This article does not contain any studies with human participants performed by any of the authors. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was not required, as this study did not involve human participants.
